Goldman predicts setbacks for Genzyme

Goldman Sachs added Genzyme to its Americas conviction sell list, saying that manufacturing setbacks at one of its plants may impair long-term growth at the company, and a near-term shortage of its drug Cerezyme may be more severe than expected. Report